Drugs / GARIVULIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03379259 | Nov 2017 → Sep 2020 | cancer | BeiGene | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GARIVULIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650449 ↗ |
| Known as | BGB-A333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03379259 ↗ |
| Action | Inhibit | “BGB-A333, a PD-L1 inhibitor” PMID 36797356 ↗ Feb 2023 |
| Modality | Monoclonal antibody | “BGB-A333 is a humanized IgG1-variant monoclonal antibody” NCT03379259 ↗ |